You are here:

entecavir, 0.5 and 1mg tablets (Baraclude)


Following a full submission

entecavir (Baraclude) is accepted for use within NHS Scotland for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase levels and histological evidence of active inflammation and or fibrosis.

Clinical studies have shown that entecavir is more effective than lamivudine in nucleosidenaïve HBeAg positive and negative patients and in lamivudine refractory patients.

Drug Details

Drug Name: entecavir, 0.5 and 1mg tablets (Baraclude)
SMC Drug ID: 320/06
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: Hepatitis B
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 October 2006